Chapter 17. The Use of RNA and CpG DNA as Nucleic Acid-Based Therapeutics

  1. Arsénio M. Fialho2 and
  2. Ananda M. Chakrabarty3
  1. Jörg Vollmer

Published Online: 18 AUG 2010

DOI: 10.1002/9780470626528.ch17

Emerging Cancer Therapy

Emerging Cancer Therapy

How to Cite

Vollmer, J. (2010) The Use of RNA and CpG DNA as Nucleic Acid-Based Therapeutics, in Emerging Cancer Therapy (eds A. M. Fialho and A. M. Chakrabarty), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470626528.ch17

Editor Information

  1. 2

    Institute for Biotechnology and Bioengineering (IBB), Center for Biological and Chemical Engineering, Instituto Superior Tecnico, Lisbon, Portugal

  2. 3

    Department of Microbiology and Immunology, University of Illinois College of Medicine, Chicago, IL, USA

Author Information

  1. Coley Pharmaceutical GmbH—A Pfizer Company, Düsseldorf, Germany

Publication History

  1. Published Online: 18 AUG 2010
  2. Published Print: 16 JUL 2010

ISBN Information

Print ISBN: 9780470444672

Online ISBN: 9780470626528



  • use of RNA and CpG DNA - as nucleic acid–based therapeutics;
  • TLR7/8 and RNA sequence recognition;
  • CpG ODN stimulation - and orchestrated immune responses via TLR9-dependent signaling


This chapter contains sections titled:

  • Toll-Like Receptor 9 and CpG DNA Sequence Recognition

  • TLR7/8 and RNA Sequence Recognition

  • Homeostasis of TLR Responses: How to Distinguish Foreign from Self

  • TLRs 7, 8, and 9 Single Nucleotide Polymorphisms and Susceptibility to Atopies, Infectious Diseases, or Systemic Lupus Erythematosus

  • CpG DNA Motifs and Beyond

  • Cell Surface and Cytoplasmic RNA Receptors: TLR3 and Retinoic Acid-Inducible Protein-I-Like Receptors

  • From Preclinical Studies to Clinical Application

  • Acknowledgment

  • References